B effector cells activated by a chimeric protein consisting of IL-2 and the ectodomain of TGF-β receptor II induce potent antitumor immunity

Keyphrases

• Receptor II 100%
• Interleukin-2 100%
• Tumor Immunity 100%
• Chimeric Protein 100%
• Effector Cells 100%
• Ectodomain 100%
• TGF-β Receptor 100%
• B Cells 75%
• Antigen Presentation 50%
• Antigen-presenting Cells 50%
• Soluble interleukin-2 Receptor (sIL-2R) 50%
• Inflammatory Cytokines 25%
• Tumor 25%
• Mouse Model 25%
• Overexpressing 25%
• CD4+ 25%
• Lymphoma 25%
• CD8+ T Cells 25%
• Lymphoid Cells 25%
• Cell-derived 25%
• Nave 25%
• Tumor Regression 25%
• Splenic B Cells 25%
• Protective Immunity 25%
• Immune Therapy 25%
• Cell Identity 25%
• T-bet 25%
• Ovalbumin 25%
• Hyperphosphorylation 25%
• Tumor Antigen 25%
• Hereafter 25%
• PAX5 25%
• B Cell Activation 25%
• CD19 25%
• Identity-based 25%
• Smad7 25%
• Tumor Challenge 25%

Immunology and Microbiology

• B Cell 100%
• Interleukin 2 100%
• Effector Cell 100%
• Antigen Presentation 66%
• Antigen-Presenting Cell 66%
• Interleukin 2 Receptor 66%
• Mouse Model 33%
• T-Helper Cell 33%
• Tumor Necrosis Factor 33%
• STAT3 33%
• Cytotoxic T-Cell 33%
• Immunotherapy 33%
• Proinflammatory Cytokine 33%
• Tumor Antigen 33%
• Innate Lymphoid Cell 33%
• Upregulation 33%
• STAT5 33%
• Splenic B Cell 33%
• B Cell Activation 33%
• CD19 33%
• Antitumor Effector Cell 33%
• In Vitro 33%

Pharmacology, Toxicology and Pharmaceutical Science

• Receptor 100%
• Interleukin 2 100%
• Interleukin 2 Receptor 100%
• Chimeric Protein 100%
• Tumor Necrosis Factor 50%
• Neoplasm 50%
• Malignant Neoplasm 50%
• Cytokine 50%
• Mouse Model 50%
• CD8 Antigen 50%
• Immunotherapy 50%
• Tumor Regression 50%
• Ovalbumin 50%
• Tumor Antigen 50%